
FDA priority-reviews zanubrutinib plus rituximab for untreated mantle cell lymphoma, showing 43% lower progression or death risk than bendamustine-rituximab.
Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the treatment of elderly patients with lymphoma.
Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the treatment of elderly patients with lymphoma.





